**Supplementary Table S1.** Main characteristics of participants according to availability of data from symptom-reporting daily diary and/or data from blood samples.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | | **Total**  **N= 1008** | **Availability of data** | | | |
| **Diary but not blood**  **N= 783** | **Both blood and diary**  **N=160** | **Blood but not diary**  **N= 65** | **p-value\*** |
| Sexual orientation, n (%) | Bisexual | 69 (6.8) | 52 (6.6) | 14 (8.8) | 3 (4.6) | 0.481 |
|  | Transgender | 12 (1.2) | 8 (1.0) | 4 (2.5) | 0 (0.0) |  |
|  | MSM | 927 (92.0) | 723 (92.3) | 142 (88.8) | 62 (95.4) |  |
| Age, years | Median (IQR) | 44 (36, 52) | 42 (37, 42) | 45 (36, 52) | 45 (36, 53) | 0.376 |
| PREP use, n (%) | No | 803 (79.7) | 639 (81.6) | 120 (75.0) | 44 (67.7) | <0.001 |
|  | Yes | 183 (18.2) | 138 (17.6) | 29 (18.1) | 16 (24.6) |  |
|  | Not reported | 22 (2.2) | 6 (0.8) | 11 (6.9) | 5 (7.7) |  |
| >=1 STI over previous year, n (%) | Yes | 229 (22.7) | 181 (23.1) | 28 (17.5) | 20 (30.8) | 0.084 |
|  | Siphilis | 109 (10.8) | 85 (10.9) | 14 (8.8) | 10 (15.4) | 0.347 |
|  | Gonorrhoea | 72 (7.1) | 58 (7.4) | 6 (3.8) | 8 (12.3) | 0.065 |
|  | Chlamydia | 37 (3.7) | 25 (3.2) | 9 (5.6) | 3 (4.6) | 0.302 |
|  | HPV | 22 (2.2) | 16 (2.0) | 3 (1.9) | 3 (4.6) | 0.379 |
|  | PLWH | 289 (28.7) | 6 (0.8) | 11 (6.9) | 5 (7.7) | <0.001 |
| PLWH on ART& | Yes | 289 (100.0) | 180 (100.0) | 81 (100.0) | 28 (100.0) |  |
| CD4 cell count&, cells/mm3, n (%) | 0-200 | 10 (3.5) | 5 (2.8) | 5 (6.2) | 0 (0.0) | 0.453 |
|  | 201-500 | 46 (15.9) | 29 (16.1) | 10 (12.3) | 7 (25.0) |  |
|  | 501+ | 232 (80.3) | 145 (80.6) | 66 (81.5) | 21 (75.0) |  |
|  | Not measured | 1 (0.3) | 1 (0.6) | 0 (0.0) | 0 (0.0) |  |
| Comorbidities, n (%) | None | 946 (93.8) | 736 (94.0) | 148 (92.5) | 62 (95.4) | 0.905 |
|  | >=1 | 39 (3.9) | 31 (4.0) | 6 (3.8) | 2 (3.1) |  |
|  | Unknown | 23 (2.3) | 16 (2.0) | 6 (3.8) | 1 (1.5) |  |
| Previous smallpox vaccination, n (%) | Yes | 157 (15.6) | 67 (8.6) | 58 (36.3) | 32 (49.2) | <0.001 |
| Route of administration, n (%) | Sub-cutaneous | 836 (84.4) | 716 (91.4) | 102 (63.8) | 33 (50.8) | <0.001 |
|  | Intra-dermic | 157 (15.6) | 67 (8.6) | 58 (36.3) | 32 (49.2) |  |

&In PLWH; \*Chi-square or Kruskall-Wallis test as appropriate

MSM: men who have sex with men; IQR: interquartile range; PrEP: pre-exposure prophylaxis for HIV infection; STI: sexually transmitted infection; HPV: human papillomavirus; PLWH: people living with HIV; ART: antiretroviral therapy.

Mild

Moderate

Severe

Missing

None